Published in Women's Health Weekly, March 5th, 2009
"In Trial I, 36 patients received docetaxel 35 mg/m(2) weekly for 6 weeks every 8 weeks and in Trial II, 29 patients received docetaxel 100 mg/m(2) day 1 every 21 days. Patient characteristics were comparable. However, patients with liver involvement comprised 25% of cases in Trial I and 55% in Trial H. The overall response rate on an intention-to-treat basis was 19% vs. 45% in Trial I and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly